



FOR IMMEDIATE RELEASE

Contact:

Risa Goldman Burgess or Ted Smith
Schwartz Communications, Inc.
781-684-0770
verdezyne@schwartz-pr.com

VERDEZYNE LANDS CONTRACT WITH NOVOZYMES

CARLSBAD, Calif.— April 13, 2009 –[Verdezyne, Inc.](http://www.verdezyne.com), a privately-held synthetic biology company developing processes for the industrial chemicals and fuel markets, today announced it has signed an agreement with Novozymes, a biotech-based world leader in enzymes and microorganisms. Under the arrangement, Verdezyne will optimize selected genes that encode industrial enzymes. These enzymes will then be manufactured in microbial systems.

“Leading industrial biotechnology companies, such as Novozymes, are quickly realizing the potential of Verdezyne’s unique core technology to optimize the expression of key enzymes,” said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. “We are looking forward to helping Novozymes meet its program goals and at the same time further demonstrate the value of our industrial biotechnology platform.”

Verdezyne employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel gene libraries for engineering proteins, metabolic pathways, and microorganisms as well as to manufacture platform chemicals and biofuels.

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Novozymes' natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 5,000 patents, showing what is possible when nature and technology join forces. Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen A/S (NZYM B). Read more at www.novozymes.com.

About Verdezyne

Founded in 2005, Verdezyne, formerly known as CODA Genomics, is a privately-held company that integrates its proprietary core technologies to direct the evolution of novel metabolic pathways for cost effective commercial production of biofuels and platform chemicals. Investors in Verdezyne include OVP Venture Partners, Monitor Ventures, Tech Coast Angels and Life Science Angels. For more information on Verdezyne, visit www.verdezyne.com.

###